Literature DB >> 30844733

Nano-engineered flavonoids for cancer protection.

Neha Bunkar1, Ruchita Shandilya1, Arpit Bhargava1, Ravindra M Samarth1, Rajnarayan Tiwari1, Dinesh Kumar Mishra2, Rupesh Kumar Srivastava3, Radhey Shyam Sharma4, Nirmal Kumar Lohiya5, Pradyumna Kumar Mishra6.   

Abstract

Diet and environment are two critical regulators that influence an individual's epigenetic profile. Besides the anterograde signaling, mitochondria act as a key regulator of epigenetic alterations in cancer either by controlling the concentration of the cofactors, activity of vital enzymes or by affecting the transcription of NF-kappaB and associated signaling molecules. As epigenetic modifications are the major drivers of aberrant gene expression, designing novel nutri-epigenomic strategies to modulate reversible epigenetic modifications will be important for effective cancer protection. In this regard, nutraceuticals such as flavonoids holds significant promise to modulate the epigenome through a network of interconnected anti-redox mechanisms. However, low solubility, rapid metabolism and poor absorption of flavonoids in gastrointestinal tract hinder their use in clinical settings. Therefore, it is imperative to develop nano-engineered systems which could considerably improve the targeted delivery of these bioactive compounds with better efficacy and pharmacokinetic properties. Concerted efforts in nano-engineering of flavonoids using polymer, lipid and complexation based approaches could provide successful bench-to-bedside translation of flavonoids as broad spectrum anti-cancer agents.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30844733     DOI: 10.2741/4771

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  2 in total

Review 1.  The Coming Age of Flavonoids in the Treatment of Diabetic Complications.

Authors:  Teresa Caro-Ordieres; Gema Marín-Royo; Lucas Opazo-Ríos; Luna Jiménez-Castilla; Juan Antonio Moreno; Carmen Gómez-Guerrero; Jesús Egido
Journal:  J Clin Med       Date:  2020-01-27       Impact factor: 4.241

2.  Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors.

Authors:  Héloïse M Leclair; Nina Tardif; Anaïs Paris; Marie-Dominique Galibert; Sébastien Corre
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.